In United States
Lupin announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg.Lupin's Metformin HCl ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.
Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCl ER Tablets, 500 mg and 1000 mg.
Glumetza HCI ER Tablets had US sales of USD 450.4 million (IMS MAT September 2015).
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app